292 related articles for article (PubMed ID: 16457636)
1. Naturally occurring and synthetic imidazoles: their chemistry and their biological activities.
De Luca L
Curr Med Chem; 2006; 13(1):1-23. PubMed ID: 16457636
[TBL] [Abstract][Full Text] [Related]
2. Imidazole Derivatives as Potential Therapeutic Agents.
Sharma A; Kumar V; Kharb R; Kumar S; Sharma PC; Pathak DP
Curr Pharm Des; 2016; 22(21):3265-301. PubMed ID: 26916016
[TBL] [Abstract][Full Text] [Related]
3. 4-(omega-(alkyloxy)alkyl)-1H-imidazole derivatives as histamine H(3) receptor antagonists/agonists.
Meier G; Krause M; Hüls A; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
J Med Chem; 2004 May; 47(10):2678-87. PubMed ID: 15115409
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of potential bisubstrate inhibitors of protein farnesyltransferase. Design and synthesis of functionalized imidazoles.
de Figueiredo RM; Coudray L; Dubois J
Org Biomol Chem; 2007 Oct; 5(20):3299-309. PubMed ID: 17912382
[TBL] [Abstract][Full Text] [Related]
5. Unexpected partial H1-receptor agonism of imidazole-type histamine H3-receptor antagonists lacking a basic side chain.
Sadek B; Elz S; Pertz HH; Stark H; Schunack W
Inflamm Res; 2004 Aug; 53 Suppl 2():S109-15. PubMed ID: 15338060
[TBL] [Abstract][Full Text] [Related]
6. Meta-substituted aryl(thio)ethers as potent partial agonists (or antagonists) for the histamine H3 receptor lacking a nitrogen atom in the side chain.
Pelloux-Léon N; Fkyerat A; Piripitsi A; Tertiuk W; Schunack W; Stark H; Garbarg M; Ligneau X; Arrang JM; Schwartz JC; Ganellin CR
J Med Chem; 2004 Jun; 47(12):3264-74. PubMed ID: 15163206
[TBL] [Abstract][Full Text] [Related]
7. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
[TBL] [Abstract][Full Text] [Related]
8. Current and Future Prospective of a Versatile Moiety: Imidazole.
Rani N; Kumar P; Singh R; de Sousa DP; Sharma P
Curr Drug Targets; 2020; 21(11):1130-1155. PubMed ID: 32472996
[TBL] [Abstract][Full Text] [Related]
9. Antifungal and antimycobacterial activity of 1-(3,5-diaryl-4,5-dihydro-1H-pyrazol-4-yl)-1H-imidazole derivatives.
Zampieri D; Mamolo MG; Laurini E; Scialino G; Banfi E; Vio L
Bioorg Med Chem; 2008 Apr; 16(8):4516-22. PubMed ID: 18321714
[TBL] [Abstract][Full Text] [Related]
10. Cholinesterase-like organocatalysis by imidazole and imidazole-bearing molecules.
Nieri P; Carpi S; Fogli S; Polini B; Breschi MC; Podestà A
Sci Rep; 2017 Apr; 8():45760. PubMed ID: 28367983
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent imidazole and cyanophenyl containing farnesyltransferase inhibitors with improved oral bioavailability.
Tong Y; Lin NH; Wang L; Hasvold L; Wang W; Leonard N; Li T; Li Q; Cohen J; Gu WZ; Zhang H; Stoll V; Bauch J; Marsh K; Rosenberg SH; Sham HL
Bioorg Med Chem Lett; 2003 May; 13(9):1571-4. PubMed ID: 12699757
[TBL] [Abstract][Full Text] [Related]
12. Medicinal chemical and pharmacological aspects of imidazole-containing histamine H3 receptor antagonists.
Stark H; Kathmann M; Schlicker E; Schunack W; Schlegel B; Sippl W
Mini Rev Med Chem; 2004 Nov; 4(9):965-77. PubMed ID: 15544557
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and initial biological evaluation of substituted 1-phenylamino-2-thio-4,5-dimethyl-1H-imidazole derivatives.
Yurttaş L; Duran M; Demirayak Ş; Gençer HK; Tunalı Y
Bioorg Med Chem Lett; 2013 Dec; 23(24):6764-8. PubMed ID: 24176398
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, antibacterial and antifungal activities of bifonazole derivatives.
El Hage S; Lajoie B; Feuillolay C; Roques C; Baziard G
Arch Pharm (Weinheim); 2011 Jun; 344(6):402-10. PubMed ID: 21433056
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of (+/-)-trans- or cis-(5-aminomethyltetrahydrofuranyl)imidazole by Mitsunobu cyclization: synthetic studies toward novel histamine H3 or H4-ligands.
Harusawa S; Araki L; Imazu T; Ohishi H; Sakamoto Y; Kurihara T
Chem Pharm Bull (Tokyo); 2003 Mar; 51(3):325-9. PubMed ID: 12612422
[TBL] [Abstract][Full Text] [Related]
17. Non-imidazole histamine NO-donor H3-antagonists.
Tosco P; Bertinaria M; Di Stilo A; Cena C; Fruttero R; Gasco A
Farmaco; 2005; 60(6-7):507-12. PubMed ID: 15927183
[TBL] [Abstract][Full Text] [Related]
18. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
Yates SL; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Tedford CE
J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699
[TBL] [Abstract][Full Text] [Related]
19. Imidazole: Synthesis, Functionalization and Physicochemical Properties of a Privileged Structure in Medicinal Chemistry.
Tolomeu HV; Fraga CAM
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677894
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antimicrobial studies of some Mannich bases carrying imidazole moiety.
Frank PV; Manjunatha Poojary M; Damodara N; Chikkanna C
Acta Pharm; 2013 Jun; 63(2):231-9. PubMed ID: 23846145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
